For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem cell transplant ...

Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public health system.

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

News 8 is once again honoring Black history by looking at health care and the racial disparities many report facing.

One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...

A new gene editing treatment has been approved for use in the NHS, which will help treat sickle cell disease patients ...

A cutting-edge gene therapy has been approved for NHS use for some patients with severe sickle cell disease. Casgevy, also known as exa-cel, was the first treatment to be licensed using gene ...

Gallbladder issues are a frequent but manageable complication of sickle cell disease. Awareness of the symptoms and risk factors, combined with regular medical care, can help patients address ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy ...